Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
Date:12/12/2011

of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new products domestically and internationally, obtaining and maintaining regulatory approvals domestically and internationally, risks associated with meeting the objectives of the PRIME study, including, but not limited to, delays or failures in enrollment, and the occurrence of adverse safety events, and risks associated with initiating a study of behavioral disturbances associated with Alzheimer's disease, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com 
+1 (949) 389-6700AVANIR PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS 

 

 

  September 30, September 30, 2011 201
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
2. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
3. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
4. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
5. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
6. Avanir Pharmaceuticals to Participate in Two Investor Conferences
7. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
8. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
9. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
10. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
11. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... ORANGE COUNTY, Calif., May 23, 2011 Applied Medical ... Healthcare (doing business as Covidien) on May 17, 2011 ... of California for infringing a recently issued Applied Medical ... Plus trocar products, Civil Action No. CV 11-4203 VBF ...
... 23, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has informed the company that it has ... be held on June 17, 2011 to discuss the Company,s ... of the neovascular form of age-related macular degeneration (wet AMD). ...
Cached Medicine Technology:Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 2FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 3FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 4
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... same odds for condition, regardless of screening , , SUNDAY, June 8 ... less risk than previously believed of having silent myocardial ischemia, a ... study. , In fact, all adults aged 55 to ... a cardiac condition whether they are screened for the problem or ...
... 7, 2008 The International Diabetes Federation (IDF) Task ... research demonstrates that type 2 diabetes and obstructive sleep ... have significant implications on public health and on individuals. ... and sleep experts who examined the impacts of untreated ...
... Organization, Carolyn,s Compassionate Children gives cancer, ... of attending college, BOSTON, June 7 ... and cancer survivor Leanna,Elizalde with a $2,500 Survivorship ... School,s graduation ceremony Saturday. Alex Oden, 20, a,two-time ...
... Distributed, Flexible, Redundant, Patient-Specific Intra-Venous, (IV) Automation Robot for Non-Hazardous ... Satellite Pharmacies, and Even ... Patient Care Workplaces, ... leader in the robotic automation of patient-specific IV,Admixtures today announced ...
... 2 diabetes risk but could suggest its causes ... identified a gene that regulates glucose levels but does ... their finding may help improve understanding of the underlying ... diagnostic of diabetes. This finding demonstrates there are gene ...
... Becomes "Susan G. Komen GLOBAL Race for the ... Mall was,passionately pink this morning, as nearly 50,000 ... the 19th annual Susan,G. Komen National Race for ... fund breast cancer research and community health programs ...
Cached Medicine News:Health News:Older Diabetics' Risk of Cardiac Ischemia Lower Than Thought 2Health News:IDF urges health care providers to address the relationship between type 2 diabetes and sleep apnea 2Health News:Nonprofit Organization Dedicated to Helping Young Adult Cancer Survivors Raises $4500 for Leanna Elizalde 2Health News:Health Robotics Announces IV Station (TM Pending) a Centrally-Controlled, 2Health News:Health Robotics Announces IV Station (TM Pending) a Centrally-Controlled, 3Health News:Scientists ID Gene Regulating Blood Glucose Levels 2Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 2Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 3
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: